Prostate artery embolization maintains its effectiveness for at least three years after patients undergo the therapy, according to research presented at the Society of Interventional Radiology’s 2017 annual scientific meeting. The study was awarded as the “Abstract of the Year”.
Isobar Compression has been awarded a research contract from the Small Business Research Initiative (SBRI) for Healthcare, to assist in a feasibly study in primary care for the treatment of venous leg ulcers.
Three-year outcomes from the VeClose US pivotal clinical trial and one-year data from the WAVES study have been presented at the 2017 CX Symposium in London, UK. Both results were presented by Kathleen Gibson (Bellevue, USA). The new data demonstrate the clinical and quality of life benefits of the Medtronic VenaSeal closure system in treating patients with venous reflux disease.
Research published in Phlebology has indicated that the 2013 UK varicose veins clinical guidelines have led to “a considerable increase” in leg ulcer patient referrals, although many patients are still not being referred early enough, the authors of the paper argue.
Inari Medical, a venture capital backed medical device company focused on the interventional treatment of venous thrombus, has announced the treatment of the first patient with its ClotTriever thrombectomy system.
Further evidence has been found by researchers at the UK’s University of Leicester and University of Bristol to suggest statins could “significantly reduce” the occurrence of blood clotting in certain parts of the body.
The use of dedicated nitinol venous stents across the inguinal ligament shows “good outcomes” in terms of patency but reinterventions may be required, according to Prakash Saha, Guy’s and St Thomas’ NHS Foundation Trust and King’s College London, London, UK, who spoke about this topic at the American Venous Forum Annual Meeting (14–17 February, New Orleans, USA). The patency rates seen with these newer devices are comparable to data reported for the Wallstent (Boston Scientific).
A Canadian-led international research team has found that the blood thinner rivaroxaban is as safe as aspirin, and more effective at preventing recurrence of life-threatening blood clots in the legs and lungs, according to a study published in the New England Journal of Medicine.
In a new study presented at the American College of Cardiology 66th Annual Scientific Session, researchers from the Perelman School of Medicine at the University of Pennsylvania have found that the utilisation rates of these potentially life-saving medications are low, particularly in the sub-group of pulmonary embolism patients who are critically ill.
The use of computerised clinical decision support systems among surgical patients are associated with a significant increase in the proportion of patients with adequately ordered treatment to prevent blood clots, and a significant decrease in the risk of developing a blood clot, according to a study published online by JAMA Surgery.
CorVascular has entered into a distribution agreement with Novarix. The IV-eye, developed and manufactured in the UK by Novarix, is a near infrared (NIR) vein imaging device designed to aid healthcare professionals in finding suitable peripheral veins for both cannulation and venipuncture.
Following Health Canada regulatory approval, BTG is to launch its polidocanol injectable foam (Varithena), a drug/device combination product used to treat varicose veins, in Canada. The product is intended for use in adults with clinically significant venous reflux as diagnosed by duplex ultrasound.
Philips has announced the global launch of Azurion, its next generation image-guided therapy platform, which forms the new core of its integrated solutions portfolio for the fast growing image-guided therapy market.
Some research data suggest there could be a synergistic effect between immunotherapy and minimally invasive procedures. Tumour types that do not respond to checkpoint inhibitors – so called “cold tumours” – could “turn hot” after treatment with locoregional therapies, writes Melanie Lee, London, UK.
BTG has announced a collaboration with the Society of Interventional Oncology (SIO; a global organisation working to nurture and support interventional oncology worldwide) to explore the role of interventional oncology alongside immuno-oncology.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos